- THIS ARTICLE
-
Abstract
- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted
- SERVICES
- Similar articles in this journal
- Similar articles in PubMed
- Alert me to new issues of the journal
- Download to citation manager
- Reprints & Permissions
- CITING ARTICLES
- Citing Articles via HighWire
- Citing Articles via Google Scholar
- GOOGLE SCHOLAR
- Articles by Mullen, J. R.
- Articles by Brill, S. J.
- Search for Related Content
- PUBMED
- PubMed Citation
- Articles by Mullen, J. R.
- Articles by Brill, S. J.
Bipartite Structure of the SGS1 DNA Helicase in Saccharomyces cerevisiae
Janet R. Mullena, Vivek Kaliramana, and Steven J. Brillaa Department of Molecular Biology and Biochemistry, Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey 08855
Corresponding author: Steven J. Brill, Department of Molecular Biology and Biochemistry, Rutgers University, 679 Hoes Ln., CABM, Piscataway, NJ 08855., brill{at}mbcl.rutgers.edu (E-mail)
Communicating editor: F. WINSTON
| ABSTRACT |
|---|
SGS1 in yeast encodes a DNA helicase with homology to the human BLM and WRN proteins. This group of proteins is characterized by a highly conserved DNA helicase domain homologous to Escherichia coli RecQ and a large N-terminal domain of unknown function. To determine the role of these domains in SGS1 function, we constructed a series of truncation and helicase-defective (-hd) alleles and examined their ability to complement several sgs1 phenotypes. Certain SGS1 alleles showed distinct phenotypes: sgs1-hd failed to complement the MMS hypersensitivity and hyper-recombination phenotypes, but partially complemented the slow-growth suppression of top3 sgs1 strains and the top1 sgs1 growth defect. Unexpectedly, an allele that encodes the amino terminus alone showed essentially complete complementation of the hyper-recombination and top1 sgs1 defects. In contrast, an allele encoding the helicase domain alone was unable to complement any sgs1 phenotype. Small truncations of the N terminus resulted in hyper-recombination and slow-growth phenotypes in excess of the null allele. These hypermorphic phenotypes could be relieved by deleting more of the N terminus, or in some cases, by a point mutation in the helicase domain. Intragenic complementation experiments demonstrate that both the amino terminus and the DNA helicase are required for full SGS1 function. We conclude that the amino terminus of Sgs1 has an essential role in SGS1 function, distinct from that of the DNA helicase, with which it genetically interacts.
THE SGS1 gene of Saccharomyces cerevisiae is a member of the RecQ family of DNA helicases that includes the human genes BLM (![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
|
Mutations in SGS1 were first identified by their ability to suppress the slow-growth phenotype of top3 strains such that top3 sgs1 double mutants grow at nearly the wild-type rate (![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
The RecQ family proteins have a central domain that is homologous to the bacterial DNA helicase (Fig 1) and as predicted, the BLM, WRN, and Sgs1 proteins have all been shown to possess 3' to 5' DNA helicase activity similar to that of RecQ (![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
We had previously created a helicase-defective allele of SGS1 (sgs1-hd) that changed a single amino acid within the ATP-binding domain of Sgs1 (K706A). Although the mutant protein lacked detectable DNA helicase activity, sgs1-hd retained noticeable complementing activity in the top3 sgs1 and top1 sgs1 backgrounds (![]()
| MATERIALS AND METHODS |
|---|
Strains:
The yeast strains used in this study are listed in Table 1. Strain construction, growth, and transformation followed standard methods (![]()
![]()
![]()
|
Recombination assay:
NJY540 cells carrying the integrated versions of the Sgs1 N- and C-terminal deletion series were grown on -ade -ura -leu plates, resuspended in water, diluted appropriately, plated onto YPD + ADE plates at ~200 cells per plate, and grown at 30°. After 3 days, seven colonies from each strain were picked, resuspended in 150 µl water, diluted, and aliquoted onto four plates: -ura and YPD at 400 cells/plate, synthetic complete medium containing 5-fluoroorotic acid (5-FOA) at 4000 cells/plate, and synthetic complete medium containing canavanine in place of arginine at 40,000 cells/plate. After 3 days at 30°, colonies were counted. The frequency of viable cells (as determined from the YPD plates) that were canavanineR or 5-FOAR (ura-) was determined as described previously and the mean value was presented as a percentage (![]()
![]()
|
|
Plasmid constructions:
Plasmid pJL31 (![]()
![]()
![]()
![]()
A C-terminal triple-HA epitope was added to the SGS1 gene of pSM100 by mutating the stop codon to a unique NotI restriction site (resulting in the addition of residues GGR to the C terminus of Sgs1) and ligating a 117-bp NotI/SacI fragment encoding 34 additional residues to Sgs1. Subsequent N-terminal deletion derivatives were constructed by moving truncation alleles on NdeI/SacII cassettes. The sgs1-
C795-HA and sgs1-
C795-myc alleles were made by fusing NotI/SacI epitope cassettes to sgs1-
C795 in which the sequence following residue 652 was similarly mutated to a NotI restriction site. The 13x-myc epitope was amplified as a NotI/SacI fragment using plasmid pFA6a-13Myc-kanMX6 (![]()
MMS sensitivity:
Methylmethanesulfonate was added to a final concentration of 0.012% in YPD agar before pouring and the plates were used within 3 days. Cells were scraped from freshly growing plates, resuspended in water, and OD600 was determined. Cells were transferred to microtiter plates in a vertical row at OD = 3.0 and serially diluted 1:5. A replica plater was then used to transfer a drop from each well to MMS and YPD plates.
Extract preparation and immunoblotting:
Yeast cells were grown in 50 ml selective media to an OD600 = 1, harvested, washed with an equal volume of water, and resuspended in 1 ml A buffer [25 mM Tris (pH 7.5), 1 mM EDTA, 0.01% NP-40, 10% glycerol, 0.1 mM PMSF, and 1 mM DTT] with 0.1 M NaCl and the following protease inhibitors: pepstatin, 10 µg/ml; leupeptin, 5 µg/ml; benzamidine, 10 mM; bacitracin, 100 µg/ml; aprotinin, 20 µg/ml; and sodium metabisulfite, 10 mM. Cells were lysed by vortexing with glass beads at 4° and the extract was collected following centrifugation for 15 min at 4°. Extract concentrations were normalized using the Bradford assay (Bio-Rad, Richmond, CA). One hundred microliters of extract was diluted with an equal volume of RIPA buffer (![]()
![]()
| RESULTS |
|---|
To identify functional domains in Sgs1, a near-complete deletion of the SGS1 gene was constructed in strain K1875 to create NJY540 (sgs1::loxP; Table 1 and MATERIALS AND METHODS). A series of truncation derivatives of the SGS1 gene was also constructed and several representative alleles are diagrammed in Fig 1B. To express these truncations, a plasmid containing the SGS1 open reading frame and 150 bp of its promoter was prepared in which the initiating methionine codon was mutated to a unique NdeI restriction site (pSM100). This parent vector then served as recipient for SGS1 truncations on NdeI/SacI cassettes that were generated by PCR amplification.
Domains of SGS1 required for growth in the presence of MMS:
sgs1 mutants have been reported to be sensitive to DNA-damaging agents (![]()
C200) allowed wild-type growth, although proteins with larger C-terminal deletions were noticeably defective. These larger C-terminal truncation alleles, such as
C795, allowed limited growth on MMS, but not wild-type levels. We conclude that full MMS resistance requires DNA helicase activity and all but the last 200 amino acids of Sgs1. We also note that whereas sgs1-hd is null, the allele
C795, which completely lacks the helicase domain, retains partial activity. This suggests that the sgs1-hd mutation may alter the function of the N terminus or the stability of the protein.
|
To address whether these mutations affected Sgs1 expression levels, a C-terminal triple-HA epitope tag was added to several truncated Sgs1 proteins and their relative expression levels were compared by immunoblot. Signals obtained by immunoblotting crude extracts were very weak, so consecutive immunoprecipitations and immunoblots were used to enhance these signals. We observed that wild-type Sgs1-HA protein migrated at 220 kD by SDS-PAGE (Fig 3). This apparent molecular weight is larger than the predicted size of 165 kD and may be due to the highly acidic amino terminus. All of the mutant proteins were stable and in some cases were overexpressed relative to the wild type; sgs1-hd and
N158 protein levels were slightly elevated, while
N322,
N644, and
C795 levels were greatly elevated. The
N158 and
N322 proteins also migrated more slowly than expected, while the
N644 protein, which consists of the very basic helicase domain alone, migrated at its expected size. The
C795 protein, which consists of the very acidic amino-terminus alone, migrated much slower than expected and was associated with a variable amount of cleaved product migrating at 110 kD. We conclude that the mutant alleles are well expressed and any loss of activity we observe is likely due to the loss of functional domains. This idea is further supported by intragenic complementation experiments described below. We also note that any potential complementing activity by these alleles might depend on their elevated expression.
|
Complementation of the sgs1 slx4 synthetic lethality:
We have identified several nonessential SLX genes that, when mutant, cause the cell to require SGS1 for viability (J. R. MULLEN, V. KALIRAMAN and S. J. BRILL, unpublished results). A strain that is null in both SGS1 and SLX4 (YLR135W) is inviable but can be maintained by a copy of SGS1 on a URA3-based plasmid. The strain NJY561 (slx4 sgs1 pJM500::SGS1 URA3) is unable to grow on media containing 5-FOA since selection against the URA3 plasmid is lethal in this background. We tested whether SGS1 truncations could complement this phenotype by transforming them into NJY561 and streaking the transformants onto media containing 5-FOA. Apart from wild-type SGS1, only
C200 was able to complement the loss of SGS1 in the slx4::loxP background (summarized in Table 5). Identical results were obtained with four other SLX mutants (data not shown). As in the MMS assay, SGS1 function requires the N terminus, the DNA helicase domain, and most of the C terminus; only the last 200 amino acids of the protein is dispensible. Finally, this assay appears more stringent than complementation of MMS hypersensitivity since no intermediate complementation was observed with SGS1 C-terminal truncations larger than
C200.
|
|
Complementation of the sgs1 hyper-recombination phenotype:
Mutations in SGS1 cause a hyper-recombination phenotype (![]()
![]()
![]()
![]()
![]()
Interestingly, a truncation of the Sgs1 amino terminus (
N158) increased the recombination to a level greater than the null frequency (1116 times over wild type). Over the course of several trials, the enhancement relative to null ranged from 1.2 to 3.3 (2.2 ± 0.9 average) for URA3 and 0.9 to 3.0 (1.7 ± 1.0 average) for CAN1. To determine if this hypermorphic phenotype was dependent on the helicase activity of the
N158 allele, we constructed the compound allele
N158-hd, which includes the K706A mutation known to inactivate the Sgs1 DNA helicase (![]()
N322, produced recombination frequencies that were equivalent to the null. The smallest C-terminal truncation (
C200) retained wild-type activity, while a truncation of 300 amino acids (aa;
C300) was null. Unexpectedly, the
C795 allele, which lacks the entire DNA helicase domain, retained significant complementing activity as it did in the MMS hypersensitivity assay. Taken together, we conclude that (1) the amino terminus of Sgs1 is necessary and sufficient for suppressing recombination; (2)
N158 is a hypermorphic allele, with some of its activity independent of DNA helicase activity; and (3) SGS1 affects recombination at RDN1 and LYS2 similarly. As in the MMS assay, the fact that sgs1-hd fails to complement as well as
C795 does suggests that the -hd mutation inhibits the activity of the amino terminus.
Complementation in the top3 sgs1 mutant background:
Role of SGS1 helicase activity:
Given the antagonistic nature of helicase-topoisomerase interactions, it is reasonable to expect that the slow growth of top3 cells might be caused by the DNA-unwinding activity of Sgs1, unchecked by Top3. However, we previously judged sgs1-hd to be active in inhibiting the growth of top3 sgs1 cells when streaked onto agar plates (![]()
|
To quantitate the activity of sgs1-hd in this assay, we used three methods. First, we picked large and small colonies from the transformation plates and measured growth rates in selective liquid medium at 30°. When top3 sgs1 cells were transformed with vector alone, the large and small colonies grew with roughly similar doubling times of 135 and 140 min, respectively. Cells transformed with SGS1 also grew at rates reflecting their colony size (205 and 235 min) as did cells transformed with sgs1-hd (210 and 155 min). We conclude that the average growth rate of sgs1-hd transformants (183 min) is intermediate to that of vector- (138 min) and SGS1- (220 min) transformed cells. In particular, even fast-growing sgs1-hd transformants grew slower than vector transformants, indicating that sgs1-hd retains partial activity in this assay. As a second method we tested how a population of top3 cells, not just a few colonies, responded to sgs1-hd. To do this, we complemented a top3 sgs1 double mutant with a TOP3/URA3 plasmid (pJM555) and one of the SGS1 alleles carried on a LEU2 plasmid. Strains carrying the two plasmids were then serially diluted and spotted on plates containing 5-FOA, to select against the TOP3/URA3 plasmid, and on control plates. As expected, cells carrying pSGS1/LEU2 grew poorly on 5-FOA/-leucine, displaying the top3 slow-growth phenotype. Cells transformed with the empty LEU2 vector grew well on 5-FOA/-leucine, displaying the top3 sgs1 phenotype of fast growth (Fig 4B). Cells carrying sgs1-hd display an intermediate phenotype, requiring an ~10-fold higher concentration of cells to equal the growth obtained with vector alone.
A third method to test the activity of sgs1-hd in the top3 sgs1 background was to place the SGS1 alleles behind the inducible GAL10 promoter and observe the effect of overexpression in the double mutant. Transformants were serially diluted and spotted onto selective plates containing either galactose or glucose. Cells transformed with vector alone grew well on both galactose and glucose, while cells transformed with SGS1 grew slowly on galactose, as expected (Fig 5). If the slow growth of top3 cells is due solely to Sgs1 helicase activity unbalanced by Top3 activity, then overexpressing sgs1-hd should have no effect. However, overexpression of sgs1-hd reduced the growth of top3 sgs1 cells such that 5- to 25-fold more sgs1-hd cells were required to equal the overall amount of growth of cells transformed with vector alone (Fig 5, bottom panels). This effect is clearly not as severe as overexpressing wild-type SGS1. Furthermore, the intermediate activity of sgs1-hd is unlikely to be due to residual helicase activity as
C795, which encodes only the N terminus, shows the same intermediate activity in this assay (Fig 4B). Presumably, the amino-terminal domain of Sgs1 must also contribute to growth suppression in the absence of Top3.
|
Role of the SGS1 amino terminus:
When the top3 sgs1 double mutant was transformed with the amino-terminal truncation alleles
N50,
N101, and
N158, we were surprised to find that the transformants grew more slowly than cells transformed with SGS1 (Fig 4A). In the case of
N158, growth was so slow that transformant colonies were not visible until 3 days at 30°, compared to SGS1 transformants that were clearly visible after 2 days. This unusual phenotype of
N158 is discussed further below. Larger truncations, such as
N322 reversed this slow-growth trend while
N644 conferred a null phenotype (Fig 4B). The null phenotype of
N644 again confirms that complementation of top3 sgs1 slow-growth suppression requires the N terminus of Sgs1 and not just DNA helicase activity. We tested whether overexpression of the helicase domain would overcome this limitation. Overexpression of the N-terminal deletions, up to and including
N644, did inhibit growth as wild-type SGS1 did (Fig 5A, top panels and data not shown). Thus, overexpression of the helicase domain alone can suppress the lack of the amino terminus. Accordingly,
N1000, which removes both the N terminus and much of the DNA helicase domain, is null in this assay. We conclude that complementation of top3 sgs1 slow-growth suppression requires both the N terminus and DNA helicase activity.
The severe growth inhibition of
N158 described above will be referred to as the "toxic effect" to distinguish it from the normal growth inhibition of wild-type SGS1 in the top3 background. The toxic effect of
N158 and its reversal by larger truncations like
N322 correlate with the
N158 hypermorphic phenotype observed in the recombination assay. To test whether this toxicity was specific to the top3 background, we transformed a sgs1 single mutant with the truncation series and found that its growth was similarly inhibited by this allele (Fig 6, left panels). We conclude that the toxic effect is specific for sgs1 mutant cells and that it is recessive since it is not observed in wild-type cells (data not shown). We tested whether the helicase activity of Sgs1 was required for the toxic effect by constructing compound alleles that included the -hd mutation. The addition of the -hd mutation alleviated the toxic effect of the small amino-terminal truncations in both the top3 sgs1 (Fig 4A, right-hand panels) and sgs1 (Fig 6, right panels) backgrounds. In the top3 sgs1 background, the colony sizes after transformation of the sgs1-hd,
N50-hd,
N101-hd, and
N158-hd alleles were similar to each other and intermediate to those obtained with vector and wild-type SGS1. These results indicate that the
N158 toxic phenotype requires both the specific amino terminal truncation and DNA helicase activity.
|
Role of the SGS1 carboxy terminus:
Sgs1 C-terminal truncations were tested for complementation in the top3 sgs1 background. As previously reported, none of the C-terminal truncation alleles, including
C200, significantly inhibited the growth of the top3 sgs1 double mutant using a colony size assay (![]()
C200 grew at rates reflecting their colony size (140 and 150 min) with an average doubling time of 145 min, relative to 220 min for SGS1 and 138 min for vector. Thus, in this assay alone,
C200 does not behave like wild type. Using the galactose overexpression assay,
C200 significantly inhibited growth in top3 sgs1 cells (Fig 5B, top panels), but this is likely due to excess helicase activity since either larger deletions (
C300) or inactivation of the helicase domain (
C200-hd) reduced this effect (Fig 5B, bottom panels). The importance of the C-terminal 200 amino acids is further emphasized by the fact that
C200-hd fails to inhibit growth as much as sgs1-hd when overexpressed. We conclude that complementation of top3 sgs1 slow-growth suppression is an extremely sensitive assay that requires the N terminus, DNA helicase activity, and the C-terminal 200 amino acids for full SGS1 activity.
Complementation in the top1 sgs1 mutant background:
sgs1 and top1 display a synergistic growth defect such that a top1 sgs1 double mutant grows more slowly than either single mutant (![]()
C795, which encodes the N terminus, grew as well as mutants transformed with wild-type SGS1, but cells transformed with
N644, which encodes the helicase, grew at a rate comparable to those transformed with vector alone (Fig 7B). We conclude that DNA helicase activity is completely dispensible in this assay. As in both the MMS hypersensitivity and hyper-recombination assays, complementation by
C795 was better than full-length sgs1-hd, suggesting that the -hd mutation inhibits the complementing activity of the N terminus.
|
The toxic effect of
N158 was apparent in the top1 sgs1 background, since it exacerbated rather than improved the growth defect (Fig 7A). When more of the N terminus was removed, as in the
N322 and
N484 alleles, the toxic effect was lost and complementing activity returned, although not at wild-type levels. Thus, the minimal complementing region is likely to lie between residues 484 and 644 of the N terminus. In contrast to other backgrounds, the toxic effect of
N158 was not alleviated by the
N158-hd mutation (Fig 7A, right panels). This, however, is consistent with the fact that complementation in this assay does not require helicase activity. Nevertheless, the complementing activity of
N322 and
N484 was adversely affected by the -hd mutation (Fig 7A, right panels). We suspect that this result is caused by the inhibitory effect of the -hd mutation on the activity of the N terminus. We conclude that, in the top1 sgs1 background, the toxic effect is independent of helicase activity.
Intragenic complementation by SGS1:
Because our assays revealed that Sgs1 contained two functional domains that could be independently manipulated, we wanted to determine if the two domains could be physically separated and still function. SGS1 truncations were subcloned into the appropriate vectors for simultaneous expression and complementation testing of two mutant alleles. Neither
N322 nor sgs1-hd individually conferred MMS resistance (Fig 2). However, when these two alleles were expressed simultaneously in sgs1 cells, they grew on MMS plates at a rate close to wild type (Fig 8, top). We also found that
N322 complemented the C-terminal truncation alleles
C795 and
C997, while complementation with
C1247 was impaired (Fig 8, top). In the most stringent test, we found that nonoverlapping N- and C-terminal helicase domains could complement. Fig 8 (middle) shows that
N644 (helicase domain) can be complemented by sgs1-hd as well as
C795 (N-terminal domain). In fact, significant growth on MMS is obtained with alleles
N644 and
C997, indicating that residues 450645 are dispensible for MMS resistance. As described above,
C1247 fails to allow optimal growth in the presence of
N644. Consistent with these results,
C795 (N-terminal domain) cannot be rescued by sgs1-hd, although it can be rescued by other N-terminal truncation alleles, including
N644 (helicase domain; Fig 8, bottom panel).
|
To confirm that SGS1 intragenic complementation is not unique to MMS hypersensitivity, we tested the more stringent assay of restoring viability to the synthetic-lethal slx4 sgs1 strain. Whereas neither
N322 nor sgs1-hd could individually restore viability in this background (Table 5), these alleles together rescued the slx4 sgs1 strain with a growth rate equivalent to wild type (Table 4). Moreover,
N644 (helicase domain) and the
C795 (N-terminal domain) together restored viability to the double mutant, although the growth rate was somewhat reduced. We conclude that Sgs1 can be expressed as functional N-terminal and DNA helicase domains, consistent with the dual functions of the protein, as revealed by truncation analysis.
Successful intragenic complementation suggests that either the two truncated Sgs1 proteins perform their functions separately or they assemble into a stable complex, as in ß-galactosidase
-complementation. To test these possibilities, we placed a myc-epitope tag on the C terminus of the N-terminal domain (
C795-myc) and expressed it with the Sgs1-HA-tagged proteins described in Fig 3. Crude extracts were made from cells coexpressing these proteins and the potential complexes were analyzed by consecutive immunoprecipitation (IP) and immunoblotting. In this experiment Sgs1-HA migrated as a doublet at 220 kD perhaps due to post-translational modification (Fig 9, top). When full-length Sgs1-HA was coexpressed with
C795-myc and immunoprecipitated with anti-myc antibody, a small amount of Sgs1-HA could be detected in the IP following blotting with anti-HA antibody (Fig 9, middle). This result suggests that Sgs1 interacts with itself in the cell, perhaps forming a multimer via the N-terminal domain. Consistent with this idea, the HA-tagged N-terminal truncation alleles failed to coprecipitate with
C795-myc. A control immunoblot with anti-myc antibody revealed that
C795-myc was expressed in these strains (Fig 9, bottom panel). These results suggest that the N terminus and helicase domain expressed during intragenic complementation do not associate in the cell and that they perform their functions separately. We cannot, however, rule out the possibility that the truncated Sgs1 proteins were complexed in the cell and were disrupted by the lysis or immunoprecipitation procedures.
|
| DISCUSSION |
|---|
As a first step toward characterizing the RecQ family of DNA helicases, we have conducted a structure/function analysis of the yeast SGS1 gene. Table 5 summarizes the results of our experiments. An unanticipated finding of these studies was that certain SGS1 alleles have distinct phenotypes depending on the assay. In assays measuring recombination or growth rates, we identified alleles with intermediate or null phenotypes in addition to hypermorphic alleles whose phenotype was more severe than the null. In contrast, in assays measuring MMS resistance or complementation of synthetic lethality, most of the intermediate and hypermorphic alleles displayed a null phenotype. Further evidence that these alleles retained partial activity was that wild-type function could be restored through intragenic complementation. We believe that certain mutant alleles display distinct phenotypes for two reasons: first, some assays differ in their sensitivity to Sgs1 activity and second, some assays require only one of Sgs1's two functional domains.
Compared to the null allele,
N158 exhibited both very high rates of recombination and toxicity in sgs1 strains, yet was null in the MMS and synthetic lethality assays (Table 5). The toxicity was most apparent in top1 sgs1 cells, where we expected any SGS1 activity to improve, not inhibit growth. And while SGS1 activity is expected to inhibit growth in the top3 background,
N158 inhibited growth even more dramatically than wild-type SGS1. The mechanism of
N158 toxicity and hyper-recombination is not understood, but it is known that overexpressing wild-type SGS1 leads to severe growth inhibition in these backgrounds (Fig 5; data not shown). Therefore, a possible explanation for the
N158 phenotype is that truncation of the N terminus creates a "hyperactive" protein. This idea is consistent with the simultaneous reduction in recombination rate and toxicity caused by the larger truncation encoded by
N322 or by a mutation in the helicase domain.
To explain these data we propose that an inhibitory domain of Sgs1 is removed by
N158, revealing a stimulatory domain that, in turn, is removed by
N322 (Fig 10A). Since removal of the stimulatory domain correlates with increased
N322 protein levels (Fig 3), the loss of the hypermorphic phenotype must be due to loss of function and not a loss of protein stability. A prediction of this model is that overexpression of wild-type SGS1 should stimulate recombination and other sgs1 phenotypes. Indeed, overexpression of SGS1 is known to induce nucleolar fragmentation, a phenotype of prematurely aging sgs1 cells (![]()
N158 hypermorphic phenotype depend on DNA helicase activity? The toxicity of
N158 in sgs1 and top3 sgs1 cells is relieved by a point mutation in the helicase domain. However,
N158-hd remains toxic in top1 sgs1 cells and causes excessive hyper-recombination in sgs1 cells even in the absence of helicase activity. Thus, the hypermorphic phenotype depends on helicase activity only when the specific assay depends on helicase activity.
|
How might the domain between residues 1 and 158 function to inhibit the activity of Sgs1? The simplest model (Fig 10B, top) proposes that a subdomain of the N terminus, N1, inhibits the DNA helicase (pathway 1), while the alternative, which we prefer, is that N1 inhibits an activity present in N2 (pathway 2). An obvious possibility is that N2 is a nuclease as in WRN (![]()
The
C795 allele, which expresses the N-terminal 652 aa alone, restored good growth to a top1 sgs1 double mutant, consistent with our previous report that a full-length helicase-defective allele was active in this assay (![]()
N484 was also able to restore good growth to top1 sgs1 cells. We conclude that the residues between 484 and 652 contain a domain that is important for good growth in the top1 background. How could this domain function to overcome a Top1 deficiency? One possibility is that it recruits an alternate topoisomerase, such as Top2, to relax excess superhelicity. Such an idea is consistent with the fact that residues 434744 of Sgs1 were found to interact with Top2 in a two-hybrid screen (![]()
When expressed under its own promoter,
C795, encoding the amino terminus alone, showed at least partial activity in complementing four phenotypes: MMS hypersensitivity, hyper-recombination, top3 sgs1 growth suppression, and top1 sgs1 slow growth. In contrast,
N644, which encodes the helicase domain alone, was null in these assays. Since intragenic complementation experiments demonstrated that the
N644 allele was expressed, we must conclude that the N terminus is at least as important to Sgs1 function as is the DNA helicase. This is surprising given that SGS1 is epistatic to TOP3 and it is thought that Sgs1 unwinds DNA strands to create a substrate for Top3 (![]()
![]()
The C-terminal truncation series revealed that the last 200 aa of Sgs1, which include the HRD domain, are dispensible for all phenotypes except complementation of top3 sgs1 slow-growth suppression. However, overexpression of
C200 causes slow growth in this background, as does
N644 (Table 5), indicating that an imbalance of helicase over Top3 activity can induce slow growth even in the absence of the N terminus. This is consistent with the fact that sgs1-hd lacks full complementation in this assay and shows that helicase activity is an important, although not exclusive, determinant in this assay. The failure of
C200 to complement would be expected if the C-terminal 200 aa are important for protein localization as in WRN (![]()
![]()
The sgs1-hd allele, which carries a point mutation in the helicase domain, was null in three assays and intermediate in complementing the top1 sgs1 growth defect and top3 sgs1 slow-growth suppression. In some of these assays (e.g., MMS hypersensitivity, hyper-recombination, and complementation of top1 sgs1 slow growth), sgs1-hd was more defective than
C795, which lacks the entire helicase domain. We suspect that the defective helicase domain inhibits the function of the amino terminus. This could be explained simply if the helicase domain interacts with other proteins such as Top3 (![]()
![]()
The dual functions of Sgs1 may extend to other RecQ family members such as the rqh1+ gene of S. pombe. The rqh1.r12 allele contains a single missense mutation in the ATP-binding domain of Rqh1 (![]()
![]()
![]()
![]()
Intragenic complementation experiments provide convincing evidence of the bipartite nature of Sgs1. These experiments confirm that the amino-terminal domain possesses an activity separate from the DNA helicase and that the two domains function in an interdependent manner. Further analysis of the enzymology of Sgs1 and its physical interactions with other proteins should shed light on this second function.
| ACKNOWLEDGMENTS |
|---|
The authors thank Sheila Mellody for expert technical assistance. This work was supported by grants from the National Institutes of Health (R01-AG16637), the American Cancer Society (RPG-98-079-01), and the Charles and Joanna Busch Memorial Fund.
Manuscript received September 9, 1999; Accepted for publication December 6, 1999.
| LITERATURE CITED |
|---|
BENNETT, R. J., J. A. SHARP, and J. C. WANG, 1998 Purification and characterization of the sgs1 DNA helicase activity of Saccharomyces cerevisiae.. J. Biol. Chem. 273:9644-9650
CHRISTMAN, M. F., F. S. DIETRICH, N. A. LEVIN, B. U. SADOFF, and G. R. FINK, 1993 The rRNA-encoding DNA array has an altered structure in topoisomerase I mutants of Saccharomyces cerevisiae.. Proc. Natl. Acad. Sci. USA 90:7637-7641
CZAPLINSKI, K., M. J. RUIZ-ECHEVARRIA, S. V. PAUSHKIN, X. HAN, and Y. WENG et al., 1998 The surveillance complex interacts with the translation release factors to enhance termination and degrade aberrant mRNAs. Genes Dev. 12:1665-1677
ELLIS, N. A., J. GRODEN, T.-Z. YE, J. STRAUGHEN, and D. J. LENNON et al., 1995 The Bloom's syndrome gene product is homologous to recQ helicases. Cell 83:655-666[Medline].
GANGLOFF, S., J. P. MCDONALD, C. BENDIXEN, L. ARTHUR, and R. ROTHSTEIN, 1994 The yeast type I topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: a potential eukaryotic reverse gyrase. Mol. Cell. Biol. 14:8391-8398
GEBHART, E., R. BAUER, U. RAUB, M. SCHINZEL, and K. W. RUPRECHT et al., 1988 Spontaneous and induced chromosomal instability in Werner syndrome. Hum. Genet. 80:135-139[Medline].
GERMAN, J., 1963 Bloom syndrome: a mendelian prototype of somatic mutational disease. Medicine 72:393-406.
GRAY, M. D., J. C. SHEN, A. S. KAMATH-LOEB, A. BLANK, and B. L. SOPHER et al., 1997 The Werner syndrome protein is a DNA helicase. Nat. Genet. 17:100-103[Medline].
GULDENER, U., S. HECK, T. FIELDER, J. BEINHAUER, and J. H. HEGEMANN, 1996 A new efficient gene disruption cassette for repeated use in budding yeast. Nucleic Acids Res. 24:2519-2524
HARLOW, E., and D. LANE, 1988 Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
HARMON, F. G., R. J. DIGATE, and S. C. KOWALCZYKOWSKI, 1999 RecQ helicase and topoisomerase III comprise a novel DNA strand passage function: a conserved mechanism for control of DNA recombination. Mol. Cell 3:611-620[Medline].
HOEHN, H., E. M. BRYANT, K. AU, T. H. NORWOOD, and H. BOMAN et al., 1975 Variegated translocation mosaicism in human skin fibroblast cultures. Cytogenet. Cell Genet. 15:282-298[Medline].
HUANG, S., B. LI, M. D. GRAY, J. OSHIMA, and I. S. MIAN et al., 1998 The premature ageing syndrome protein, WRN, is a 3'
5' exonuclease. Nat. Genet. 20:114-116. [letter][Medline].
JOHNSTON, M. and R. W. DAVIS, 1984 Sequences that regulate the divergent GAL1-GAL10 promoter in Saccharomyces cerevisiae.. Mol. Cell. Biol. 4:1440-1448
KANEKO, H., K. O. ORII, E. MATSUI, N. SHIMOZAWA, and T. FUKAO et al., 1997 BLM (the causative gene of Bloom syndrome) protein translocation into the nucleus by a nuclear localization signal. Biochem. Biophys. Res. Commun. 240:348-353[Medline].
KAROW, J. K., R. K. CHAKRAVERTY, and I. D. HICKSON, 1997 The Bloom's syndrome gene product is a 3'-5' DNA helicase. J. Biol. Chem. 272:30611-30614
KEIL, R. L. and A. D. MCWILLIAMS, 1993 A gene with specific and global effects on recombination of sequences from tandemly repeated genes in Saccharomyces cerevisiae.. Genetics 135:711-718[Abstract].
LONGTINE, M. S., A. MCKENZIE, III, D. J. DEMARINI, N. G. SHAH, and A. WACH et al., 1998 Additional modules for versatile and economical PCR-based gene deletion and modification in Saccharomyces cerevisiae.. Yeast 14:953-961[Medline].
LU, J., J. R. MULLEN, S. J. BRILL, S. KLEFF, and A. ROMEO et al., 1996 Human homologs of yeast DNA helicase. Nature 383:678-679[Medline].
MATSUMOTO, T., A. SHIMAMOTO, M. GOTO, and Y. FURUICHI, 1997 Impaired nuclear localization of defective DNA helicases in Werner's syndrome. Nat. Genet. 16:335-336[Medline].
MOROZOV, V., A. R. MUSHEGIAN, E. V. KOONIN, and P. BORK, 1997 A putative nucleic acid-binding domain in Bloom's and Werner's syndrome helicases. Trends Biochem. Sci. 22:417-418[Medline].
MURRAY, J. M., H. D. LINDSAY, C. A. MUNDAY, and A. M. CARR, 1997 Role of Schizosaccharomyces pombe RecQ homolog, recombination, and checkpoint genes in UV damage tolerance. Mol. Cell. Biol. 17:6868-6875[Abstract].
MUSHEGIAN, A. R., D. E. BASSETT, JR., M. S. BOGUSKI, P. BORK, and E. V. KOONIN, 1997 Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs. Proc. Natl. Acad. Sci. USA 94:5831-5836. [see comments]
PURANAM, K. L. and P. J. BLACKSHEAR, 1994 Cloning and characterization of RECQL, a potential human homologue of the Escherichia coli DNA helicase RecQ. J. Biol. Chem. 269:29838-29845
ROSE, M. D., F. WINSTON and P. HIETER, 1990 Methods in Yeast Genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
SIKORSKI, R. S. and P. HIETER, 1989 A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae.. Genetics 122:19-27
SINCLAIR, D. A. and L. GUARENTE, 1997 Extrachromosomal rDNA circlesa cause of aging in yeast. Cell 91:1033-1042[Medline].
SINCLAIR, D. A., K. MILLS, and L. GUARENTE, 1997 Accelerated aging and nucleolar fragmentation in yeast sgs1 mutants. Science 277:1313-1316









